AgeX Q1 2023 net loss widens to $3.3M; cash only $0.3M; going concern flagged

Serina Therapeutics, Inc.

2024-Q1 EPS reported $0.20 revenue$10,000

Cash, cash equivalents and restricted cash totaled $0.3M as of March 31, 2023.
Owed Juvenescence $33.6M in principal and origination fees; secured note line increased by $4M on May 9.
Q1 revenue $10K (up from $5K YoY); operating expenses $2.2M vs $2.1M.
Net loss attributable to AgeX $3.3M ($0.09 per share) vs $2.7M ($0.07) in prior year.
Company expresses substantial doubt about ability to continue as a going concern.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Serina Therapeutics, Inc. reported quarter ended March 31, 2023 results: revenue $10,000, net income $3.3 million, EPS ($0.09) per share (basic and diluted).

Period: quarter ended March 31, 2023
Revenue: $10,000
Net income: $3.3 million
EPS: ($0.09) per share (basic and diluted)
Result: reported results

Exact text from the filing

and fund each of AgeX’s future draws of that additional amount of credit. First Quarter 2023 Operating Results Revenues: Total Revenues for the first quarter of 2023 were $10,000 as compared with $5,000 in the same period in 2022. Revenues are entirely comprised of sales of research products including stem cell products. Operating expenses: Operating

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.